Phase 3 Study Evaluating IMBRUVICA ® (ibrutinib) in Combination with Rituximab in Waldenström’s Macroglobulinemia Met Primary Endpoint

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news